Axsome Therapeutics (AXSM) Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Do insiders & institutionals believe in AXSM or JAZZ?

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more volatility and risk, AXSM or JAZZ?

Axsome Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

Do analysts prefer AXSM or JAZZ?

Axsome Therapeutics currently has a consensus target price of $172.33, indicating a potential upside of 58.13%. Jazz Pharmaceuticals has a consensus target price of $184.00, indicating a potential upside of 66.86%. Given Jazz Pharmaceuticals' higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	3.06
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

Is AXSM or JAZZ more profitable?

Jazz Pharmaceuticals has a net margin of 11.86% compared to Axsome Therapeutics' net margin of -64.39%. Jazz Pharmaceuticals' return on equity of 26.62% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-64.39%	-272.80%	-36.69%
Jazz Pharmaceuticals	11.86%	26.62%	9.14%

Does the media refer more to AXSM or JAZZ?

In the previous week, Axsome Therapeutics had 6 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 15 mentions for Axsome Therapeutics and 9 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.90 beat Jazz Pharmaceuticals' score of 0.58 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, AXSM or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$432.16M	12.42	-$287.22M	-$5.77	-18.89
Jazz Pharmaceuticals	$4.07B	1.64	$560.12M	$7.50	14.70

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.